Effect of volatile oil of amomum on expressions of platelet activating factor and mastocarcinoma-related peptide in the gastric membrane of chronic gastritis patients with helicobacter-pylori infection.
OBJECTIVE: To observe the effect of volatile oil of amomum (VOA) on the expressions of mastocarcinoma-related peptide (PS2) and platelet activating factor (PAF) in helicobacter pyloriassociated gastritis (HPG) and to analyze its potential mechanism. METHODS: Eighty patients with HPG were randomly as...
| Publicado en: | Chinese Journal of Integrative Medicine Vol. 14; no. 1; pp. 23 - 28 |
|---|---|
| Formato: | Journal Article |
| Publicado: |
Springer Nature
Mar2008
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105773475&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 105773475 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 16720415 1CAP jtl: Chinese Journal of Integrative Medicine issn: 16720415 maglogo: N pubinfo: dt: Mar2008 vid: 14 iid: 1 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 105773475 2009899359 NLM18568325 105773475 ppf: 23 ppct: 5 formats: tig: atl: Effect of volatile oil of amomum on expressions of platelet activating factor and mastocarcinoma-related peptide in the gastric membrane of chronic gastritis patients with helicobacter-pylori infection. aug: sug: subj: Essential Oils Therapeutic Use Gastric Mucosa Gastritis Drug Therapy Helicobacter Infections Drug Therapy Helicobacter Pylori Peptides Analysis Phospholipids Analysis Plants Adult Aged Blotting, Western Chronic Disease Essential Oils Adverse Effects Female Gastritis Metabolism Helicobacter Infections Metabolism Immunohistochemistry Male Middle Age Adult: 19-44 years Aged: 65+ years Middle Aged: 45-64 years Female Male ab: OBJECTIVE: To observe the effect of volatile oil of amomum (VOA) on the expressions of mastocarcinoma-related peptide (PS2) and platelet activating factor (PAF) in helicobacter pyloriassociated gastritis (HPG) and to analyze its potential mechanism. METHODS: Eighty patients with HPG were randomly assigned to two groups, 42 patients in the treated group treated with 0.5 mL VOA, thrice per day; and the 38 patients in the control group receiving Western tertiary medicinal treatment. Gastroscopic picture and helicobacter pylori (HP) infection (by quick urease and Warthin-Starry stain) of the gastro-membrane, expressions of PS2 and PAF (by immunohistochemical assay and Western blotting) as well as the contents of aminohexose and phospholipid (by Neuhaus method) in the gastric membrane of all patients were detected before treatment and 4 weeks after treatment. The clinical efficacy in the two groups was compared. RESULTS: The total effective rate in the treated group was 88.1%, which was significantly higher than that in the control group (78.9%, P<0.05). After treatment, in the treated group, gastric membranous contents of aminohexose and phospholipid was increased, expression of PS2 elevated but that of PAF lowered, all showing significant difference as compared with those in the control group (P<0.01). In the control group, the expressions of PS2 and PAF changed insignificantly. The radical eliminating rate of HP in the treated group and the control group was insignificantly different between them (76.1% vs. 65.8%, P>0.05). CONCLUSION: The mechanism of VOA for anti-gastritis might be related with its action in increasing the expression of PS2 and decreasing the expression of PAF, and thus regulating the hydrophobicity of the gastric membrane. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|